Non Invasive Prenatal Testing Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global non invasive prenatal testing market growth forecasted to transform from USD 7.2 billion in 2024 to USD 14.1 billion by 2029, driven by a CAGR of 14.5%. The primary growth factors propelling this market include spiking investments, incentives, and support from both state governments and private companies, which are driving access to and demand for NIPT technologies. Also, the growing shift from invasive techniques to non-invasive ones is a crucial market growth driver. Since these tests provide a secure option for the identification of genetic defects in the fetus and do not pose problems similar to invasive methods like amniocentesis, this is another area of importance that research has indicated. Nevertheless, the market expansion still has some roadblocks to tackle. These reasons include the high price of NIPT, which has made it difficult to access in low and middle-income countries. However, the pace of technological advancement and the growing end-user awareness will ensure that the market continues to expand in the coming years.

Non Invasive Prenatal Testing Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Non Invasive Prenatal Testing Market Dynamics

DRIVER: Growing preference for non-invasive techniques over invasive methods

Invasive prenatal diagnostic tests have been in use for years, such as amniocentesis and chorionic villus sampling. Usually, they are applied when anomalies are indicated by ultrasonography and biochemical screening tests. Although they have diagnostic value, they are risky and can lead to miscarriage. The American Pregnancy Association says the risk of miscarriage from amniocentesis is between 1 in 400 and 1 in 200; the more frequently they are performed, the lower the risk—closer to 1 in 400. The miscarriages from these procedures may be a result of uterine infections, premature rupture of membranes, or early labor. This is nearly the same as the rate associated with CVS; about 1 procedure in 100 cases results in a miscarriage.

As a reaction to the cited risks, new non-invasive prenatal testing technologies have emerged as a safer and better alternative. It tends to have much-prolonged benefits, which include more safety in the procedure, no operative complications, and no risk to the pregnancy and the unborn child. This method uses effective means in screening aneuploidies without incurring the risk of causing a miscarriage. Considering that there is major technological progress, the NIPT technologies have become of interest to expectant mothers and their respective healthcare providers. This means that NIPT has gained more popularity in many countries as the standard practice for pregnant women screening; thus, the global market of NIPT has been picking up steadily.

RESTRAINT: High cost of procedures

The high cost of non-invasive prenatal testing procedures limits its wide-scale adoption. NIPT technologies require state-of-the-art laboratory set-ups and specialized techniques for analyzing cell-free fetal DNA. These are highly complex processes that come with the cost of development and operation, which may be transferred to the healthcare providers and reflected in the fees charged to the patient. NIPT, therefore, may turn out to be much more expensive than the conventional forms of prenatal screening. It may be unaffordable for the majority of expectant parents, given how much of the global population lacks adequate insurance or lives in areas with limited health care coverage. The resulting high cost prohibits the use of this technology despite the fact that NIPT can correctly identify cases of chromosomal abnormalities with minimum risk compared to the invasive procedures of amniocentesis or chorionic villus sampling. Because of the uncertainty of reimbursement models or low reimbursement rates from insurance companies, healthcare providers and institutions do not readily purchase NIPT infrastructure.

The return on investment in relation to providing NIPT services may be challenging to achieve financially, especially in environments where patient volumes are low or healthcare budgets are tight. For instance, although the price for an NIPT test may differ from USD 100 to over USD 2,000 in the US, it differs between USD 60 and USD 600 in India. Such costs may vary due to local health infrastructure, insurance policies, and the balance between private and public health systems. This economic challenge is considered to be a main restraint for the global NIPT market.

OPPORTUNITY: Technological advancement

Recent technological advances have only made non-invasive prenatal testing more precise and increased scope. Using next-generation sequencing, together with bioinformatics algorithms, allows comprehensive screening and detection of major chromosomal abnormalities, including but not limited to Down syndrome, Edwards syndrome, and Patau syndrome, to be conducted very sensitively and specifically. Greater accuracy allows less follow-up of additional invasive procedures and helps in raising confidence, increasing NIPT’s uptake. The aggregate effect of these new technologies is to ensure the efficacy of and extend NIPT diagnostics to more types of conditions, including microdeletion syndrome and single-gene disorders, thus becoming a more comprehensive method of prenatal diagnostics. This creates a feature that boosts clinical utility and, therefore, the market potential.

The other source of the rising cost for NIPT is the cost reductions from technological advancements, which are increasing through better laboratory automation, efficient data analysis, and streamlined sample processing. These cost reductions make even NIPT more affordable, particularly in cost-sensitive markets and places where expensive procedures are unavailable. The process of sample collection and processing has also been augmented technologically and significantly simplified, such that only very small amounts of blood are needed, and the turnaround times have been reduced drastically.

CHALLENGE: Lack of skilled professionals

The job requirements are enormous: personnel assigned to NIPT must be familiar with or able to work on sequencing systems, PCR systems, and ultrasound equipment while still processing large chunks of data. For instance, the US alone faces a challenging shortage of more than 7,000 lab professionals for its laboratories on an annual basis. The country has to contend with the fact that the annual production of laboratory technical workforce education programs is only 6,000. Another 20,000 to 25,000 laboratory technologists are required for the industry, with only 335,000 in employment, which highlights a deficit of 7% in the number of technologists needed to meet the needs of every 1,000 citizens.

This gap in skilled labor creates large barriers to the application of proper genetic analysis testing methods, which critically depend on the knowledge of proper techniques and instruments. Unskilled personnel can lead to unproductive practices and misinterpretation of sequencing data, bringing about wrong diagnoses and critical delays. This undermines the benefits of NIPT, reduces consumer confidence in the test results, and has the potential to slow down the market.

Non-Invasive Prenatal Testing Market Ecosystem

In this report, the non-invasive prenatal testing market is segmented based on product & service, method, application, end user, and region.

Products segment has accounted for the largest market share in the non invasive prenatal testing industry, by product and service.

The products segment should hold the largest share in the non invasive prenatal testing market, based on the type of product and service, due to the growing demand for increased and advanced accurate detection of fetal genetic conditions at an early stage. This can be attributed to a few market drivers, such as significant technological advancement, high awareness levels among expectant parents, and an increased incidence of chromosomal disorders. In addition, increased adoption has also resulted from the fact that the nature of the tests allows adopting it in a manner that reduces the hazard to both the mother and the fetus substantially compared to the nature of the invasive approaches. As a result, these non-invasive tests of prenatal nature have become the favorite in prenatal screening. The high preference that is racked by these tests has gained the market of the product large hikes in demand and enough dominance.

By method, cfDNA in maternal plasma test segment has accounted for the second-largest market share in the non invasive prenatal testing industry.

The non invasive prenatal testing market has been studied on the basis of the techniques used, which have been classified as segments. These include biochemical screening, ultrasound detection, and cell-free DNA (cfDNA) tests. These cfDNA in maternal plasma tests are associated with high accuracy and the possibility of early detection. Firstly, cfDNA tests are characterized by high sensitivity and specificity in detecting chromosomal abnormalities such as Down, Edwards, and Patau syndromes. The tests can be conducted as early as the 10th week of pregnancy, allowing early enough reassurance and enabling timely decision-making. The technique is also absolutely safe for the fetus itself compared to invasive procedures, such as amniocentesis, which only increases the popularity and fast implementation of cfDNA testing in practice.

Trisomy segment accounted for the largest market share in the non invasive prenatal testing industry, by application.

In the market for non invasive prenatal testing applications, the dominant segment has been trisomy. The demand for trisomy detection is the primary growth driver for this market. Technological upgrades have bolstered the test’s precision and accuracy, increasing the confidence of expectant parents and healthcare providers in these tests. Better accuracy in diagnosis and determining trisomy 21, trisomy 18, and trisomy 13 ensures an early diagnosis and a successful outcome of a pregnancy. Technological advancements will support the adoption of NIPT among healthcare providers and patients; it is expected to become the preferred method of screening for trisomy.

By end user type, diagnostic laboratories segment witnessed the fastest CAGR in the non invasive prenatal testing industry

The diagnostic laboratories segment is projected to be the fastest-growing segment in the non invasive prenatal testing market, primarily due to the increasing adoption of advanced technologies for genetic testing worldwide. These laboratories have always been pioneers in high-end NIPT platforms with a high degree of sensitivity and specificity in detecting chromosomal abnormalities. The increasing demand from healthcare providers and parents for accurate and early detection alternatives stimulates a constant increase in the capabilities of diagnostic laboratories. This growth is driven by the laboratories’ commitment to providing cutting-edge, non-invasive, cost-effective testing solutions in a manner that further accelerates their market expansion.

North America accounted for the largest market share in the non invasive prenatal testing industry during the forecast period.

North America leads in the market for non-invasive prenatal testing due to the region’s sound healthcare infrastructure. The fallout of well-established healthcare infrastructure across the US and Canada is the wide availability of up-to-date medical technologies, firmly established healthcare set-ups, and sustainable frameworks corresponding to genetic research and development. Further, the dominance of the North American region in the NIPT market stems from the high awareness and acceptance of prenatal testing among healthcare providers and expecting parents, coupled with favorable government policies and insurance coverage. This entire infrastructure makes early adoption and consistent growth in the services of NIPT possible across this region.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the non-invasive prenatal testing market include Illumina, Inc. (US), Natera, Inc. (US), Laboratory Corporation of America Holdings (US), Eurofins Scientific (France), F. Hoffmann-La Roche AG (Switzerland), Revvity, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies (US), GE HealthCare Technologies Inc. (US), Quest Diagnostics Incorporated (US), Sonic Healthcare Limited (Australia), CENTOGENE N.V. (GERMANY), QIAGEN N.V. (GERMANY), PathWest Laboratory Medicine WA (Australia), Myriad Genetics Inc. (US), BGI Genomics Co., Ltd. (China), Oxford Nanopore Technologies Plc. (UK), MedGenome (India), Neuberg Diagnostics (India), Annoroad Gene Technology (China), Next Biosciences (South Africa), Lilac Insights (India), Invitae Corporation (US), Baylor Genetics (US), and Ravgen (US).

Non Invasive Prenatal Testing Market Report Scope

The research report categorizes the non invasive prenatal testing market to forecast revenue and analyze trends in each of the following submarkets:

By Product Service

• Products
• Services

By Method

• Ultrasound Detection
• Biochemical Screening Tests
• Cell-free DNA in Maternal Plasma Tests

By Application

• Trisomy
• Microdeletion Syndrome
• Other Applications

By End User

• Diagnostic Laboratories
• Hospitals

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLA)
• Middle East & Africa
  • GCC Countries
  • Rest of Middle East and Africa

Recent Developments Non Invasive Prenatal Testing Market

• In June 2024, Illumina, Inc. (US) announced the launch of DRAGEN v4.3, the latest version of its DRAGEN software, part of the Illumina Connected Software portfolio, for analysis of next-generation sequencing data.
• In January 2024, Natera, Inc. (US) announced that it had acquired certain assets from Invitae Corporation (US) related to Invitae’s non-invasive prenatal screening and carrier screening business.
• In August 2023, Illumina, Inc. (US) announced a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India.
• In April 2023, PerkinElmer, Inc. (US) completed the divestiture of its Applied, Food, and Enterprise Services businesses to New Mountain Capital. As a result, Post-spinoff, PerkinElmer, Inc. (US) rebranded the remaining Diagnostics and Life Sciences business as Revvity, Inc. (US).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst